Current reports

Appointment of a Member of the Management Board of Medicalgorithmics S.A.

Current report no.: 73/2022

Date of preparation: December 6, 2022.

Legal basis: Article 56 par. 1 point 2 of the Act on Public Offering – current and periodic information.

Management Board of Medicalgorithmics S.A. (“Company”) informs that on December 6, 2022, the Supervisory Board of the Company appointed Mr. Przemysław Tadla as a Member of the Management Board for a 3-year term of office.

Information about the Member of the Management Board:

Mr. Przemysław Tadla has 23 years of professional experience gained in large, international corporations operating in the electronics, automotive, product certification and medical industries.

Since 2008, he has been dealing with the assessment of compliance with safety requirements and the certification of products for the US market and the most important international markets. From Medicalgorithmics S.A. he was tied up from mid-2013 to 2021. He held several positions, including the head of the Strategy Development Department and the Plenipotentiary for the Quality Management System at the Management Board. As the Strategy Director, he was responsible for supporting the Company’s Management Board in developing, communicating, implementing and maintaining the Company’s strategic initiatives. Among the most important projects for which he was responsible was the design of the new system for hybrid cardiac rehabilitation PocketECG CRS, which ended with CE and FDA certification in 2018. In addition, for many years as the Product Compliance Director, he supervised the Company’s medical device certification department, which was responsible for all regulatory matters regarding medical devices, including certificates and registrations around the world. In the last period of work for Medicalgorithmics S.A. as the Operations Director, he managed the Company’s production plant.

After leaving Medicalgorithmics S.A. started his activity as a consultant in RASC Sp. z o. o. and cooperated with companies from the med-tech industry from Europe and the United States, supporting them in the field of product development, certification and marketing approval strategies. From the beginning of 2022, as the Operations Director, he is responsible for product development in American startups Biometryks LLC and Kardiolytics Inc.

Mr. Przemysław Tadla is a graduate of the Poznań University of Technology and post-graduate studies at the Warsaw School of Economics.

Mr. Przemysław Tadla will be responsible for the technology area in the Management Board as Chief Technology Officer.

Mr. Przemysław Tadla made a statement that he is not listed in the Register of Insolvent Debtors kept pursuant to the Act on the National Court Register, nor does he perform any activity that is competitive to the Company’s activity and that he is not a partner in competitive civil partnerships or partnerships, capital or members of bodies of other competing legal entities.